faricimab
Vabysmo (Bispecific Antibody)
Plain-language definition
A bispecific antibody targeting both VEGF and Ang-2 for wet AMD and DME, often allowing longer intervals between injections. Brand name: Vabysmo.
Where this term comes up
“Faricimab (Vabysmo)”
Treatment · Intravitreal Injection
“Faricimab (Vabysmo) and longer-interval anti-VEGF options for selected patients”
Condition · Diabetic Macular Edema (DME)
“Faricimab (Vabysmo): also targets Ang-2”
Condition · Wet Age-Related Macular Degeneration (Wet AMD)
- Category
- Medication
- Also written as
- No alternate forms listed.
Medication terms describe drugs or drug classes that may be used in eye care, neurology, inflammation, infection, or pain treatment.
Related glossary terms
- aflibercept
Eylea (Anti-VEGF)
- anti-VEGF
Anti-Vascular Endothelial Growth Factor
- bevacizumab
Avastin (Off-Label Anti-VEGF)
- ranibizumab
Lucentis (Anti-VEGF)
- macula
Central Retina
- brolucizumab
Beovu (Anti-VEGF)
A note on medical context
A glossary definition can explain a word, but it cannot tell you whether a symptom or test result is serious. If this term came from an article, use the full article and your clinician's guidance for context.